This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pore, N. Articles by Maity, A. Search for Related Content PubMed PubMed Citation Articles by Pore, N. Articles by Maity, A.

PTEN Mutation and Epidermal Growth Factor Receptor Activation Regulate Vascular Endothelial Growth Factor (VEGF) mRNA Expression in Human Glioblastoma Cells by Transactivating the Proximal VEGF Promoter¹

Departments of Radiation Oncology [N. P., S. L., A. M.] and Neurosurgery [D. M. O.], University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, and Department of Radiation Oncology, University of California, San Francisco, California 94143 [D. A. H-K.]

Our previous work showed that, compared with parental U87MG human glioblastoma cells, vascular endothelial growth factor (VEGF) mRNA levels are decreased in U87/T691, a derivative line in which epidermal growth factor receptor (EGFR) signaling is inhibited by introduction of a truncated p185^Neu protein (A. Maity et al., Cancer Res., 60: 5879–5886, 2000). The effect of EGFR activation on VEGF was mediated at the level of transcription via a phosphatidylinositol 3'-kinase (PI3K)-dependent pathway. In the current study we investigated the effect of PTEN, a negative regulator of PI3K signaling commonly mutated in glioblastoma cells, on VEGF expression. Several glioblastoma cell lines containing mutant PTEN, including U87MG, U87/T691, and U251MG, were infected with adenovirus expressing wild-type PTEN. This led to a decrease in the levels of both VEGF mRNA and phosphorylated Akt, a marker for PI3K activation. Treatment of U87MG cells with LY294002, a PI3K inhibitor, or cotransfection with a vector expressing wild-type PTEN decreased VEGF promoter activity using reporters containing either 1.5 kb of the promoter or a fragment extending from -88 to +54 bp. Activity of the -88/+54 VEGF promoter was down-regulated by dominant negative Akt and up-regulated by constitutively active myristoylated Akt. Introduction of wild-type PTEN and pharmacological inhibition of EGFR decreased VEGF mRNA expression and VEGF promoter activity in U87MG cells to a greater extent that did either manipulation by itself. Therefore, in human glioblastoma cells, PTEN mutation can cooperate with EGFR activation to increase VEGF mRNA levels by transcriptionally up-regulating the proximal VEGF promoter via the PI3K/Akt pathway.

This article has been cited by other articles:

				B. L. Lee, W. H. Kim, J. Jung, S. J. Cho, J.-W. Park, J. Kim, H.-Y. Chung, M. S. Chang, and S. Y. Nam A hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer Carcinogenesis, January 1, 2008; 29(1): 44 - 51. [Abstract] [Full Text] [PDF]

				L. Martin and R. Schilder Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition J. Clin. Oncol., July 10, 2007; 25(20): 2894 - 2901. [Abstract] [Full Text] [PDF]

				E. P. Jane, D. R. Premkumar, and I. F. Pollack Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1070 - 1080. [Abstract] [Full Text] [PDF]

				D. C. Birle and D. W. Hedley Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol. Cancer Ther., October 1, 2006; 5(10): 2494 - 2502. [Abstract] [Full Text] [PDF]

				C. Park, K. Lavine, Y. Mishina, C.-X. Deng, D. M. Ornitz, and K. Choi Bone morphogenetic protein receptor 1A signaling is dispensable for hematopoietic development but essential for vessel and atrioventricular endocardial cushion formation Development, September 1, 2006; 133(17): 3473 - 3484. [Abstract] [Full Text] [PDF]

				N. Pore, Z. Jiang, H.-K. Shu, E. Bernhard, G. D. Kao, and A. Maity Akt1 Activation Can Augment Hypoxia-Inducible Factor-1{alpha} Expression by Increasing Protein Translation through a Mammalian Target of Rapamycin-Independent Pathway Mol. Cancer Res., July 1, 2006; 4(7): 471 - 479. [Abstract] [Full Text] [PDF]

				N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms. Cancer Res., March 15, 2006; 66(6): 3197 - 3204. [Abstract] [Full Text] [PDF]

				F. Y. Wu, S. E. Wang, M. E. Sanders, I. Shin, F. Rojo, J. Baselga, and C. L. Arteaga Reduction of Cytosolic p27Kip1 Inhibits Cancer Cell Motility, Survival, and Tumorigenicity Cancer Res., February 15, 2006; 66(4): 2162 - 2172. [Abstract] [Full Text] [PDF]

				M.A. GRANT and R. KALLUR Structural Basis for the Functions of Endogenous Angiogenesis Inhibitors Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 399 - 417. [Abstract] [PDF]

				J. A. Staverosky, L. L. Muldoon, S. Guo, A. J. Evans, E. A. Neuwelt, and G. M. Clinton Herstatin, an Autoinhibitor of the Epidermal Growth Factor (EGF) Receptor Family, Blocks the Intracranial Growth of Glioblastoma Clin. Cancer Res., January 1, 2005; 11(1): 335 - 340. [Abstract] [Full Text] [PDF]

				J. Lei, C. N. Mariash, and D. H. Ingbar 3,3',5-Triiodo-L-thyronine Up-regulation of Na,K-ATPase Activity and Cell Surface Expression in Alveolar Epithelial Cells Is Src Kinase- and Phosphoinositide 3-Kinase-dependent J. Biol. Chem., November 12, 2004; 279(46): 47589 - 47600. [Abstract] [Full Text] [PDF]

				N. Pore, S. Liu, H.-K. Shu, B. Li, D. Haas-Kogan, D. Stokoe, J. Milanini-Mongiat, G. Pages, D. M. O'Rourke, E. Bernhard, et al. Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1-independent Mechanism Mol. Biol. Cell, November 1, 2004; 15(11): 4841 - 4853. [Abstract] [Full Text] [PDF]

				G. Lammering, T. H. Hewit, M. Holmes, K. Valerie, W. Hawkins, P.-S. Lin, R. B. Mikkelsen, and R. K. Schmidt-Ullrich Inhibition of the Type III Epidermal Growth Factor Receptor Variant Mutant Receptor by Dominant-Negative EGFR-CD533 Enhances Malignant Glioma Cell Radiosensitivity Clin. Cancer Res., October 1, 2004; 10(19): 6732 - 6743. [Abstract] [Full Text] [PDF]

				A. M. Arsham, D. R. Plas, C. B. Thompson, and M. C. Simon Akt and Hypoxia-Inducible Factor-1 Independently Enhance Tumor Growth and Angiogenesis Cancer Res., May 15, 2004; 64(10): 3500 - 3507. [Abstract] [Full Text] [PDF]

				F. L. Sciacca, E. Ciusani, A. Silvani, E. Corsini, S. Frigerio, S. Pogliani, E. Parati, D. Croci, A. Boiardi, and A. Salmaggi Genetic and Plasma Markers of Venous Thromboembolism in Patients with High Grade Glioma Clin. Cancer Res., February 15, 2004; 10(4): 1312 - 1317. [Abstract] [Full Text] [PDF]

				G. Stoica, H.-T. Kim, D. G. Hall, and J. R. Coates Morphology, Immunohistochemistry, and Genetic Alterations in Dog Astrocytomas Vet. Pathol., January 1, 2004; 41(1): 10 - 19. [Abstract] [Full Text] [PDF]

				A. Zetser, Y. Bashenko, H.-Q. Miao, I. Vlodavsky, and N. Ilan Heparanase Affects Adhesive and Tumorigenic Potential of Human Glioma Cells Cancer Res., November 15, 2003; 63(22): 7733 - 7741. [Abstract] [Full Text] [PDF]